Delivery Of Intracellular-Acting Biologics In Pro-Apoptotic Therapies

We have collected information about Delivery Of Intracellular-Acting Biologics In Pro-Apoptotic Therapies for you. Follow the links to find out details on Delivery Of Intracellular-Acting Biologics In Pro-Apoptotic Therapies.


Delivery of Intracellular-acting Biologics in Pro ...

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564970/
    Delivery of Intracellular-acting Biologics in Pro-Apoptotic Therapies. ... where the targeted molecule is localized pose significant challenges that limit the ability to directly apply intracellular-acting, pro-apoptotic biologics for therapeutic use. Thus, approaches to improve the pharmaceutical properties of therapeutic biomacromolecules are ...Author: Hongmei Li, Chris E. Nelson, Brian C. Evans, Craig L. Duvall

(PDF) Delivery of Intracellular-Acting Biologics in Pro ...

    https://www.researchgate.net/publication/50194912_Delivery_of_Intracellular-Acting_Biologics_in_Pro-Apoptotic_Therapies
    Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies Article · Literature Review (PDF Available) in Current pharmaceutical design 17(3):293-319 · February 2011 with 302 Reads

Delivery of Intracellular-Acting Biologics in Pro ...

    http://www.eurekaselect.com/73598
    However, stability in the in vivo environment, tumor-specific biodistribution, cell internalization, and localization to the intracellular microenvironment where the targeted molecule is localized pose significant challenges that limit the ability to directly apply intracellular …Author: Hongmei Li, Chris E. Nelson, Brian C. Evans, Craig L. Duvall

Delivery of intracellular-acting biologics in pro ...

    http://europepmc.org/articles/PMC3564970
    Jan 01, 2011 · However, stability in the in vivo environment, tumor-specific biodistribution, cell internalization, and localization to the intracellular microenvironment where the targeted molecule is localized pose significant challenges that limit the ability to directly apply intracellular-acting, pro-apoptotic biologics for therapeutic use.

Intracellular delivery of therapeutic antibodies into ...

    https://www.nature.com/articles/s41598-019-55091-0
    Dec 10, 2019 · The number of approved biologics is steadily increasing with 12 novel antibody therapeutics having gained approval in either the European …Author: Julie Gaston, Nicolas Maestrali, Guilhem Lalle, Marie Gagnaire, Alessandro Masiero, Bruno Dumas, Tar...

Publications - Duvall Advanced Therapeutics Laboratory

    https://my.vanderbilt.edu/duvall/publications/
    Harnessing albumin as a carrier for cancer therapies. Advanced drug delivery reviews. July 2018. PMID:30012492 ... Delivery of Intracellular-acting Biologics in Pro-Apoptotic ... W. Gray, N. Murthy, H. Li, CL Duvall. “Bioinspired pH-Responsive Polymers for the Intracellular Delivery of Biomolecular Drugs.” Comprehensive ...

Pro-apoptotic peptides-based cancer therapies: challenges ...

    https://link.springer.com/article/10.1007/s12272-018-1038-y
    May 26, 2018 · Pro-apoptotic peptides-based cancer therapies: challenges and strategies to enhance therapeutic efficacy ... Evans BC, Duvall CL (2011) Delivery of intracellular-acting biologics in pro-apoptotic therapies. Curr Pharm Des 17:293 ... Jun D, Ge Z (2016) iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor ...Author: Kyoung Ah Min, Pooja Maharjan, Songhee Ham, Meong Cheol Shin

Novel polymeric nanoparticles for intracellular delivery ...

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089982/
    Jun 15, 2014 · NuBCP-9 was linked to the D-Arg octamer r8 for intracellular delivery, a modification that has been reported to decrease selectivity by inducing BCL-2-independent cell killing involving membrane disruption . In the present work, delivery of NuBCP-9 into cancer cells by the polymeric NPs was achieved without the need for the R8 PTD.Author: Manoj Kumar, Dikshi Gupta, Gurpal Singh, Sapna Sharma, Madhusudan Bhat, C K Prashant, A K Dinda, Sur...

(PDF) Aminodextran Containing Magnetite Nanoparticles for ...

    https://www.researchgate.net/publication/40893143_Aminodextran_Containing_Magnetite_Nanoparticles_for_Molecular_Biology_Applications_Preparation_and_Evaluation
    Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies. ... promising advances in delivery of pro-apoptotic biomacromolecular agents have been made using tools such as peptide ...

Current Pharmaceutical Design, Volume 17 - Number 3

    https://benthamscience.com/journals/current-pharmaceutical-design/volume/17/issue/3/
    Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies , 17 ( 3 ): 293 - 319 Hongmei Li, Chris E. Nelson, Brian C. Evans and Craig L. Duvall

Searching for Delivery Of Intracellular-Acting Biologics In Pro-Apoptotic Therapies?

You can just click the links above. The data is collected for you.

Related Delivery Info